Hao Yan

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 10

Top Topics

Drug Administration

Metastatic Colorectal Cancer

Tyrosine Kinase

Top Venues

Archives of toxicology

Nature communications

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Expert opinion on pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Miaomiao Yu, Jiajia Chen, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan, Xiaochun Yang
Development and safety of PI3K inhibitors in cancer. Archives of toxicology (2023)
Hao Yan, Wentong Wu, Yuhuai Hu, Jinjin Li, Jiangxin Xu, Xueqin Chen, Jiangxin Xu, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nature communications 14 (1) (2023)
Miaomiao Yu, Jiajia Chen, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan, Xiaochun Yang
Development and safety of PI3K inhibitors in cancer. Archives of toxicology 97 (3) (2023)
Hao Yan, Wentong Wu, Yuhuai Hu, Jinjin Li, Jiangxin Xu, Xueqin Chen, Jiangxin Xu, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nature communications 14 (1) (2023)
Miaomiao Yu, Jiajia Chen, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan, Xiaochun Yang
Development and safety of PI3K inhibitors in cancer. Archives of toxicology 97 (3) (2023)
Miaomiao Yu, Jiajia Chen, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan, Xiaochun Yang
Development and safety of PI3K inhibitors in cancer. Archives of toxicology 97 (3) (2023)
Miaomiao Yu, Jiajia Chen, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan, Xiaochun Yang
Development and safety of PI3K inhibitors in cancer. Archives of toxicology 97 (3) (2023)
Hao Yan, Wentong Wu, Yuhuai Hu, Jinjin Li, Jiangxin Xu, Xueqin Chen, Jiangxin Xu, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nature communications 14 (1) (2023)
Hao Yan, Xiangliang Huang, Jiangxin Xu, Ying Zhang, Jiajia Chen, Zhifei Xu, Hui Li, Zeng Wang, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Chloroquine Intervenes Nephrotoxicity of Nilotinib through Deubiquitinase USP13-Mediated Stabilization of Bcl-XL. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Yourong Zhou, Yiming Yin, Jiangxin Xu, Jiangxin Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan, Xiaochun Yang
An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer. Expert opinion on pharmacotherapy (2023)